“A Prospective, Multi-Center Clinical Utility Study Demonstrates That the 40-Gene Expression Profile (40-GEP) Test Impacts Clinical Management for Medicare-Eligible Patients With High-Risk Cutaneous Squamous Cell Carcinoma (cSCC)”. SKIN The Journal of Cutaneous Medicine 6, no. 6 (November 16, 2022): 482–496. Accessed April 18, 2025. https://skin.dermsquared.com/skin/article/view/1788.